COGI urged the Virginia Governor to veto a recently passed bill creating a Prescription Drug Affordability Board, HB 1724. We have real concerns that a PDAB may lead to more aggressive utilization management by payers, whether related to selected drugs or products treating the same condition. The bill does not protect against this likely response impacting formulary placement of drugs, thereby entrenching existing health disparities when patients cannot get the drug that would be most effective. The bill also does not protect against the use of cost effectiveness measures that devalue patients with serious chronic and disabling conditions. View the letter here.
